Anik

GGal

Active member
Bought ANIK. Expecting their revenues from the knee osteoarthritis product to grow.

GA
 
Anika Therapeutics (ANIK - commentary - Cramer's Take - Rating) advanced 24.6% to $14.40 following word that it received an approvable letter from the Food and Drug Administration for its cosmetic tissue augmentation product. CTA is an injectable soft-tissue filler for facial wrinkles, scar remediation and lip augmentation. The final approval is expected by the end of the year
 
Back
Top